KLRK1 and myelodysplastic syndrome: NKG2D-based CAR-T or CAR-NK cells have been investigated for the treatment of multiple hematological malignancies including mainly acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) (16–18, 60, 62, 74), T-acute lymphoblastic leukemia (ALL) (17), lymphoma including B (35) or T cell lymphoma (19), and multiple myeloma (MM) (16, 19, 61).